Efficacy and safety of recombinant human type Ⅱ tumor necrosis factor receptor-Fc fusion protein combined with methotrexate in the treatment of moderate to severe rheumatoid arthritis

Subjects

Subjects :

Pharmacology
Moderate to severe
business.industry
Pharmaceutical Science
Human type
medicine.disease
law.invention
Fc fusion
law
Rheumatoid arthritis
Drug Discovery
Cancer research
Recombinant DNA
Medicine
Methotrexate
business
Tumor necrosis factor receptor
medicine.drug

Details

ISSN :

16712838

Volume :

13

Database :

OpenAIRE

Journal :

Pharmaceutical Care and Research

Accession number :

edsair.doi...........6ed6e2f80dd924a6ac599c30f55b9b7d

Full Text :

https://doi.org/10.5428/pcar20130408